Updates on the Treatment Approach for MCL
Results From a Phase 1/2 Study of Tandem, Bispecific Anti-CD20/Anti-CD19 (LV20.19) CAR T-Cells for MCL
By
ASH 2022 Conference Coverage
FEATURING
Nirav Shah
By
ASH 2022 Conference Coverage
FEATURING
Nirav Shah
Login to view comments.
Click here to Login
Updates on the Treatment Approach for MCL